Hospital Sued After Nurse Allegedly Battled Drug Addiction and Two Patients Died
A Pennsylvania hospital is facing a federal lawsuit after two whistleblower nurses accused leadership of ignoring repeated warnings about a nurse allegedly struggling with drug and alcohol addiction — a situation they claim contributed to the deaths of two patients.
The lawsuit centres on Heritage Valley Sewickley Hospital, where two nurses, Jennifer Duckett and Samantha Gallo, allege hospital administrators failed to act despite numerous reports about emergency department nurse Nolan Chismire’s alleged substance abuse and drug diversion.
According to court filings, the lawsuit was originally filed in April 2025 but was officially opened in federal court this month. The complaint names the hospital, senior clinical leaders, and Chismire himself as defendants.
At the heart of the allegations is a disturbing claim: that Chismire repeatedly stole controlled substances from the hospital for personal use while continuing to treat patients in the emergency department.
The whistleblower nurses claim hospital management was made aware of the problem multiple times but failed to intervene.
Court documents allege Chismire would divert medications including narcotics and sedatives intended for patients, sometimes replacing them with saline or improperly documenting disposal to cover his tracks. One report claims he would leave the unit to use the stolen drugs in staff bathrooms or even in his vehicle before returning to patient care.
The lawsuit alleges this conduct directly contributed to two patient deaths.
While the exact circumstances surrounding the deaths have not been fully disclosed publicly, the whistleblowers argue that impaired care, delayed treatment, and medication tampering created life-threatening risks for patients under his supervision.
The case also raises broader allegations against the hospital itself.
According to the complaint, Heritage Valley Health System is accused of fraudulent billing practices tied to the alleged drug diversion. The plaintiffs claim leadership falsified or allowed false documentation to make it appear that stolen medications had been administered appropriately to patients, when in fact they may have been diverted.
If proven, that could significantly widen the legal implications beyond negligence and into potential healthcare fraud.
The whistleblower nurses also claim they faced retaliation after reporting concerns.
Their lawsuit argues that instead of investigating thoroughly or removing the nurse from duty sooner, hospital leadership allegedly dismissed concerns and allowed unsafe practices to continue.
Federal investigators reportedly became involved earlier this year, but the lawsuit claims Chismire continued diverting drugs even after investigators had visited the hospital.
Neither the nurse nor hospital executives have publicly responded in detail to the latest allegations.
The case has sparked concern throughout the nursing and healthcare community because drug diversion remains one of the most serious threats inside hospitals.
When healthcare workers steal controlled substances, the risks go beyond addiction.
Patients may receive incorrect doses, delayed treatment, contaminated replacements, or no medication at all — each carrying potentially deadly consequences.
Drug diversion by nurses has been at the centre of several major hospital scandals in recent years across the United States, leading to tighter regulations, stronger monitoring systems, and increased scrutiny around medication dispensing practices.
Healthcare experts say this case highlights why internal reporting systems must be taken seriously.
Whistleblowers often serve as the first line of defence in identifying dangerous behaviour before patients are harmed.
For the families involved, the lawsuit could bring answers about whether stronger intervention could have prevented tragedy.
For hospitals nationwide, it serves as another reminder of the critical balance between supporting staff with substance abuse issues and protecting patient safety at all costs.
The federal case is still in its early stages, and further details are expected to emerge as proceedings continue.
